Quantinno Capital Management LP Purchases 137,758 Shares of Ultragenyx Pharmaceutical Inc. $RARE

Quantinno Capital Management LP boosted its holdings in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 276.9% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 187,508 shares of the biopharmaceutical company’s stock after acquiring an additional 137,758 shares during the quarter. Quantinno Capital Management LP owned approximately 0.19% of Ultragenyx Pharmaceutical worth $3,928,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Assenagon Asset Management S.A. increased its stake in shares of Ultragenyx Pharmaceutical by 1,030.4% during the 1st quarter. Assenagon Asset Management S.A. now owns 2,257,671 shares of the biopharmaceutical company’s stock worth $47,298,000 after purchasing an additional 2,057,951 shares during the last quarter. Jacobs Levy Equity Management Inc. raised its holdings in shares of Ultragenyx Pharmaceutical by 614.1% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 2,167,729 shares of the biopharmaceutical company’s stock valued at $65,205,000 after purchasing an additional 1,864,164 shares in the last quarter. Norges Bank acquired a new stake in shares of Ultragenyx Pharmaceutical in the 4th quarter valued at $29,004,000. Millennium Management LLC lifted its stake in shares of Ultragenyx Pharmaceutical by 787.6% in the 4th quarter. Millennium Management LLC now owns 880,644 shares of the biopharmaceutical company’s stock valued at $20,255,000 after purchasing an additional 781,431 shares during the last quarter. Finally, Vestal Point Capital LP bought a new stake in Ultragenyx Pharmaceutical in the third quarter worth $22,560,000. 97.67% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

RARE has been the topic of several analyst reports. Wall Street Zen raised shares of Ultragenyx Pharmaceutical from a “sell” rating to a “hold” rating in a research report on Saturday. Cantor Fitzgerald upped their price target on Ultragenyx Pharmaceutical from $84.00 to $96.00 and gave the stock an “overweight” rating in a research note on Thursday, May 21st. Guggenheim lowered their price objective on Ultragenyx Pharmaceutical from $43.00 to $35.00 and set a “buy” rating on the stock in a report on Tuesday. Royal Bank Of Canada raised their price objective on Ultragenyx Pharmaceutical from $35.00 to $40.00 and gave the company an “outperform” rating in a research note on Tuesday, July 7th. Finally, Wedbush reduced their target price on Ultragenyx Pharmaceutical from $27.00 to $26.00 and set a “neutral” rating for the company in a report on Wednesday, May 6th. One research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $57.82.

Ultragenyx Pharmaceutical Price Performance

Shares of RARE opened at $25.91 on Friday. The company has a market capitalization of $2.55 billion, a PE ratio of -4.44 and a beta of 0.35. Ultragenyx Pharmaceutical Inc. has a one year low of $18.29 and a one year high of $39.89. The company’s fifty day moving average price is $27.89 and its 200 day moving average price is $24.80.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported ($0.90) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.22) by $0.32. The company had revenue of $214.00 million during the quarter, compared to analysts’ expectations of $183.08 million. Ultragenyx Pharmaceutical had a negative net margin of 81.79% and a negative return on equity of 1,024.42%. The business’s quarterly revenue was up 28.5% compared to the same quarter last year. During the same period in the prior year, the company earned ($1.17) earnings per share. Analysts anticipate that Ultragenyx Pharmaceutical Inc. will post -4.46 earnings per share for the current year.

Insiders Place Their Bets

In related news, CFO Howard Horn sold 4,653 shares of the business’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $23.77, for a total transaction of $110,601.81. Following the completion of the transaction, the chief financial officer owned 105,689 shares of the company’s stock, valued at approximately $2,512,227.53. The trade was a 4.22% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Corazon (Corsee) D. Sanders sold 2,000 shares of the stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $25.05, for a total value of $50,100.00. Following the sale, the director owned 21,095 shares of the company’s stock, valued at approximately $528,429.75. The trade was a 8.66% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 14,292 shares of company stock valued at $351,644. Company insiders own 5.20% of the company’s stock.

Ultragenyx Pharmaceutical Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.